<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03104322</url>
  </required_header>
  <id_info>
    <org_study_id>IPF patientMpower 02</org_study_id>
    <nct_id>NCT03104322</nct_id>
  </id_info>
  <brief_title>Patient-reported Monitoring of Symptoms and Spirometry Via the patientMpower Platform in Idiopathic Pulmonary Fibrosis</brief_title>
  <official_title>A Randomised, Crossover Study of Self-monitoring of Symptoms and Spirometry Via the patientMpower Platform in Patients With Idiopathic Pulmonary Fibrosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>patientMpower Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Health Service Executive, Ireland</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>patientMpower Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Pilot-scale, open-label, fixed-order, two-period crossover study in idiopathic pulmonary
      fibrosis (IPF) over 16 weeks. Patients will use an electronic health journal (patientMpower
      platform) to record treatment compliance, forced vital capacity (FVC; daily), impact of IPF
      on daily life (weekly) and other symptoms. Objectives are to characterise acceptability of
      patientMpower platform from patient &amp; healthcare professional perspective, impact of active
      engagement and self-monitoring using patientMpower platform on Patient Reported Outcome
      Measures (PROMs) in IPF, impact of patientMpower platform on medication compliance and
      correlation between patient-reported PROMs &amp; FVC and clinical outcomes.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">June 15, 2017</start_date>
  <completion_date type="Actual">March 9, 2018</completion_date>
  <primary_completion_date type="Actual">March 9, 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>Fixed-order, two-period crossover (2 x 8 weeks), no washout, usual care controlled</intervention_model_description>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Acceptability of patientMpower platform from patient &amp; healthcare professional perspective</measure>
    <time_frame>8 weeks</time_frame>
    <description>Questionnaire-based assessment</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Medication compliance (days medication taken/observation period days)</measure>
    <time_frame>8 weeks</time_frame>
    <description>Compliance recorded by patient via patientMpower platform daily</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>IPF Patient Reported Outcome Measure</measure>
    <time_frame>8 weeks</time_frame>
    <description>Impact of IPF on daily life recorded via patientMpower platform weekly</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient-reported exercise performance</measure>
    <time_frame>8 weeks</time_frame>
    <description>Activity (steps/day or distance/day) recorded via patientMpower platform</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient-reported forced vital capacity</measure>
    <time_frame>8 weeks</time_frame>
    <description>Forced vital capacity recorded via patientMpower platform daily</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">7</enrollment>
  <condition>Idiopathic Pulmonary Fibrosis</condition>
  <arm_group>
    <arm_group_label>Observation sequence</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Period 1: patientMpower platform+usual care for 8 weeks; Period 2: usual care alone for 8 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>patientMpower platform</intervention_name>
    <description>electronic health journal for patient to record compliance, spirometry, impact on daily life and symptoms</description>
    <arm_group_label>Observation sequence</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>usual care</intervention_name>
    <description>usual care</description>
    <arm_group_label>Observation sequence</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  confirmed diagnosis of idiopathic pulmonary fibrosis (IPF).

          -  daily unrestricted access to smartphone or tablet device at home.

          -  demonstrated understanding of protocol and correct use of Spirobank Smart spirometer
             and patientMpower platform.

          -  able and willing to perform spirometry every day at home.

          -  willing to give written informed consent

        Exclusion Criteria:

          -  significant confusion or any concomitant medical condition which would limit the
             ability of the patient to record symptoms or use a home spirometer on a regular basis.

          -  new prescription of antifibrotic therapy for IPF (e.g. pirfenidone, nintedanib) within
             4 weeks before baseline visit.

          -  recent exacerbation of IPF or other clinically significant change in the patient's
             medical condition in 4 weeks before baseline visit
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dept. of Respiratory Medicine</last_name>
    <role>Principal Investigator</role>
    <affiliation>Galway University Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Dept. of Respiratory Medicine</name>
      <address>
        <city>Galway</city>
        <country>Ireland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Ireland</country>
  </location_countries>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 27, 2017</study_first_submitted>
  <study_first_submitted_qc>March 31, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">April 7, 2017</study_first_posted>
  <last_update_submitted>April 5, 2018</last_update_submitted>
  <last_update_submitted_qc>April 5, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 6, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>digital health</keyword>
  <keyword>home spirometry</keyword>
  <keyword>patient reported outcome measure</keyword>
  <keyword>e-health</keyword>
  <keyword>pirfenidone</keyword>
  <keyword>nintedanib</keyword>
  <keyword>FVC</keyword>
  <keyword>antifibrotic</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fibrosis</mesh_term>
    <mesh_term>Pulmonary Fibrosis</mesh_term>
    <mesh_term>Idiopathic Pulmonary Fibrosis</mesh_term>
    <mesh_term>Idiopathic Interstitial Pneumonias</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

